CLAIMS

1. Use of a *N. meningitidis* conjugate vaccine in the manufacture of a medicament for the prevention or treatment of *N. meningitidis* disease wherein a human patient is immunised in a schedule comprising steps a) and b) wherein step a) immunises the human patient at a first age of between 0 and 11 months with a bacterial saccharide conjugate vaccine comprising at least one, two or three bacterial saccharide(s) conjugated to a carrier protein to form at least one, two or three bacterial saccharide conjugate(s) ; and step b) immunises the human patient at a second age of between 12 and 24 months with a *Neisseria meningitidis* conjugate vaccine comprising at least two capsular saccharides selected from the group consisting of *N. meningitidis* serogroup A capsular saccharide (MenA), *N. meningitidis* serogroup C capsular saccharide (MenC), *N. meningitidis* serogroup W135 capsular saccharide (MenW135), and *N. meningitidis* serogroup Y capsular saccharide (MenY) conjugated separately to a carrier protein, wherein the *Neisseria meningitidis* conjugate vaccine is co-administered with a vaccine comprising diphtheria toxoid and tetanus toxoid.

2. Use according to claim 1 wherein the at least one, two or three bacterial saccharide(s) of step a) comprises a *Haemophilus influenza* (Hib) saccharide.

3. Use according to claim 1 or 2 wherein the at least one, two or three bacterial saccharide(s) of step a) comprises a *N.meningitidis* serogroup C (MenC) capsular saccharide.

4. Use according to any one of claims 1-3 wherein the at least one, two or three bacterial saccharide(s) of step a) comprises a *N. meningitidis* serogroup Y (MenY) capsular saccharide.

5. Use according to any one of claims 1-4 wherein the carrier protein of step a) is tetanus toxoid, diphtheria toxoid or CRM197.

6. Use according to claim 5 wherein the carrier protein of step a) is tetanus toxoid, optionally at a total TT content of 5-40, 10-30, 15-20μg or about 18μg per dose.

7. Use according to any one of claims 1-6 wherein the immunisation of step a) involves the administration of 2 or 3 doses of the bacterial saccharide conjugate, optionally at 2, 4 and 6 months of age.

8. Use according to any one of claims 1-7 wherein co-adminstration of the *Neisseria meningitidis* conjugate vaccine and the vaccine comprising diphtheria toxin and tetanus toxin in step b) leads to an at least 10% increase in immunogenity against at least one of MenA, MenC, MenW135 or MenY compared to where the *Neisseria meningitidis* conjugate vaccine is administered alone, optionally measured by SBA assay.

9. Use according to any one of claims 1-8 wherein during step a) the bacterial saccharide conjugate vaccine is administered at the same time as a vaccine comprising DTP.

10. Use according to any one of claims 1-9 wherein the *N. meningitidis* conjugate vaccine of step b) comprises MenA.

11. Use according to any one of claims 1-10 wherein the *N. meningitidis* conjugate vaccine of step b) comprises MenC.

12. Use according to any one of claims 1-11 wherein the *N. meningitidis* conjugate vaccine of step b) comprises MenW135.

13. Use according to any one of claims 1-12 wherein the *N. meningitidis* conjugate vaccine of step b) comprises MenY.

14. Use according to any one of claims 1-13 wherein the carrier protein of step b) is selected from the group consisting of tetanus toxoid, diphtheria toxoid or CRM197.

15. Use according to claim 14 wherein the carrier protein of step b) is tetanus toxoid.

16. Use according to any one of claims 1-15 wherein the carrier protein of step a) and the carrier protein of step b) are the same.

17. Use according to any one of claims 1-16 wherein step b) immunises the human patient at between 12 and 18 months of age.

18. Use according to claim 17 wherein step b) immunises the human patient at between 15-18 months of age.

19. Use according to any one of claims 1-18 comprising a further step c) of immunising the human patient at a third age of between 4 and 20, 5 and 15 or 5 and 11 years with a *N. meningitidis* conjugate vaccine comprising at least two capsular saccharides selected from the group consisting of *N. meningitidis* serogroup A capsular saccharide (MenA), *N. meningitidis* serogroup C capsular saccharide (MenC), *N. meningitidis* serogroup W135 capsular saccharide (MenW135), and *N. meningitidis* serogroup Y capsular saccharide (MenY) conjugated separately to a carrier protein.

20. Use of a *N. meningitidis* conjugate vaccine in the manufacture of a medicament for immunising against *Neisseria meningitidis* infection wherein a human patient is immunised at an age of between 12 and 24 months with a multivalent *N. meningitidis* conjugate vaccine comprising at least two capsular saccharides selected from the group consisting of *N. meningitidis* serogroup A capsular saccharide (MenA), *N. meningitidis* serogroup C capsular saccharide (MenC), *N. meningitidis* serogroup W135 capsular saccharide (MenW135), and *N. meningitidis* serogroup Y capsular saccharide (MenY) conjugated separately to a carrier protein and the human patient is re-immunised at an age of between 4 and 20, 5 and 15, 5 and 11, 5 and 9 or 5 and 6 years with a boosting *N. meningitidis* conjugate vaccine comprising at least two of MenA, MenC, MenW135 and MenY, each conjugated separately to a carrier protein.